Endocrine Abstracts

Introduction: Pancreatic neuroendocrine tumors (pNETs) are a heterogeneous group with various treatment options depending on grading, staging, and presence of symptoms related to hormonal secretion. Their incidence significantly increased over the past decade and nowadays constitutes 30% of all NETs of the gastrointestinal tract. Despite the evidence of a different malignancy potential of PNETs G2, postoperative management is the same in all patients. Ai...

Background: PRRT is an effective treatment option (especially for controlling disease progression)for disseminated neuroendocrine tumors (NETs), with good expression of the somatostatin receptors. Despite significant progress in NET personalized management, searching for novel predictive and prognostic factors of response to PRRT is crucial for more effective follow-up, better treatment choices leading to more favorable final outcome. Some recent studies indicate that the resp...

Paragangliomas are rare neuroendocrine neoplasms that arise from chromaffin tissue commonly located in the adrenal medulla, pre-aortic and paravertebral sympathetic plexus or skull base. About 30% of paragangliomas have a genetic basis. They may be associated with autosomal dominant inheritance of variants in the gene encoding succinate dehydrogenase or may coexist in genetically determined endocrine syndromes. The study aim was to analyse clinical and molecular data of patien...

Introduction: Due to the frequent occurrence of adrenal incidentalomas, diagnosis of their hormonal activity is a significant clinical concern. Approximately 7-10% of adrenal tumors are pheochromocytomas, which even in silent form can lead to hemodynamic instability during surgery. According to the ESE and ENSAT guidelines in any case of adrenal tumors greater than 1 cm pheochromocytoma should be excluded based on plasma metanephrines level and urinary metanephrines excretion....

Background: Although in most cases insulinomas are small and benign tumors, in about 4% they are malignant, mainly in course of inherited syndromes like MEN1, tubular sclerosis or neurofibromatosis type 1. While in case of benign tumors surgery is usually curative, the metastatic form brings difficulties in managing due to dissemination and the risk of recurring, life-threating, severe hypoglycemias. To elucidate the clinical differences between sporadic and MEN-1 linked insul...

Background: Although gastroenteropancreatic neuroendocrine tumors G3 (GEP-NET G3) and neuroendocrine cancers (GEP-NEC G3) are characterized in histopathological examination by Ki67>20% or >20 mitoses/10HPF their management and prognosis is substantially different. Despite the WHO introduces the novel well-differentiated neuroendocrine tumour of high grade (NET G3) classification in 2017 the clinical management of them is still challenging due to high NET G3 heterogenei...

Up to 40% of pheochromocytoma cases have a genetic background. The prevalence of pheochromocytoma in neurofibromatosis type 1 (NF1) was reported to be from 0.1 to 5.7%. However, the actual incidence of pheochromocytoma in NF1 seems to be underestimated. Current recommendations on NF1 do not include systematic biochemical screening for the presence of pheochromocytoma. Our aim was to analyse clinicopathological characteristics of pheochromocytoma in the course of NF1 syndrome w...

Mesenteric paragangliomas are a rare entity; consequently, 20 cases have been reported to date. Although often found incidentally and considered benign, they have potential to metastasize. We present a case of 63-year old man with a 11-year history of the mesenteric paraganglioma. The lesion for the first time had been described on CT scan of the abdomen in 2010. However, the patient was lost to follow-up. In 2021 CT scan, followed by MRI of the abdomen, perfomed due to reccur...

BackgroundSomatostatin analogues (SSA) (octreotide and lanreotide) are recommended as a first line treatment of locally advanced or metastatic well-differentiated neuroendocrine tumors (NETs) with a good expression of somatostatin receptor (SSTR). Both of them are usually used in injection repeated every 4 weeks.The study objectiveWas to compare the way of SSA administration (injection performed by profession...

Pheochromocytoma and paraganglioma (PPGL) are rare neuroendocrine tumours, which derive from the chromaffin cells of the adrenal medulla or extra-adrenal sympathetic and parasympathetic ganglia. About 15-20% of those neoplasms could present malignant course. Prediction of PPGL metastatic potential still remains a great clinical challenge, since the sensitivity and specificity of proposed prediction systems are not satisfactory. We performed a retrospective database search for ...